Stelexis Therapeutics

Stelexis Therapeutics, created by Deerfield and wholly owned by a cancer treatment company based in New York, is on a mission to transform the paradigm of cancer treatment and patient care through the discovery and development of novel drugs. Stelexis’ proprietary platform focuses on identifying, isolating, and studying the earliest definable stem cells and progenitor cells that possess clonal characteristics and pre-cancerous changes, which drive the formation of primary and recurrent human tumors. Stelexis leverages this powerful platform as a target identification engine and a drug discovery and development tool to address unmet needs across various cancer indications. Deerfield co-founded Stelexis Therapeutics in 2017 with the scientific founders, Drs.